Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617826 | 0.95 | HPGD (0.55) | ALDH1A1MAPK1MAPTLMNATDP1 | |
| SCHEMBL1619123 | 0.83 | TP53 (0.46) | ALDH1A1MAPK1MAPTTDP1L3MBTL1 | |
| SCHEMBL1618951 | 0.83 | KDM4E (0.39) | ALDH1A1LMNATDP1HPGDMEN1 | |
| SCHEMBL1619405 | 0.81 | KDM4E (0.49) | ALDH1A1MAPK1MAPTTDP1L3MBTL1 | |
| SCHEMBL1619379 | 0.81 | KDM4E (0.41) | ALDH1A1MAPK1MAPTTDP1MEN1 | |
| SCHEMBL1619203 | 0.80 | CHRM1 (0.43) | ALDH1A1MAPK1MAPTTDP1MEN1 | |
| SCHEMBL2668397 | 0.80 | KDM4E (0.38) | ALDH1A1MAPTTDP1SMN1; SMN2POLB | |
| SCHEMBL1619269 | 0.80 | KMT2A (0.49) | ALDH1A1MAPK1MAPTTDP1L3MBTL1 | |
| SCHEMBL2642742 | 0.79 | FAAH (0.41) | ALDH1A1MAPK1LMNATDP1HPGD | |
| SCHEMBL1619176 | 0.79 | RAB9A (0.39) | ALDH1A1MAPTTDP1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | claimed |
| EP-1951706-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | claimed |
| WO-2007053662-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | claimed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | claimed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | BIAN HAIYAN | 2009-08-13 | — | — | US | disclosed |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | BIAN HAIYAN | 2009-08-13 | — | — | US | disclosed |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | BIAN HAIYAN | 2009-08-13 | — | — | US | disclosed |
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| EP-1951706-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007053662-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053662-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | GCK, GCKR, GPR119 | ALDH1A1 1644/4885MAPK1 940/4885MAPT 3048/4885 |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | GCK, GCKR, GPR119 | ALDH1A1 1711/4885MAPK1 873/4885MAPT 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.